NuCana presents cash runway into 2029 in corporate presentation
NCNA•NuCana said its cash position is expected to fund operations into 2029, with approximately $25.9 million in cash and cash equivalents at June 30, 2026. The company also outlined ongoing and planned studies of NUC-7738 and NUC-3373.
1. Cash and clinical programs
NuCana said its cash position is expected to fund operations into 2029; cash and cash equivalents totaled approximately $25.9 million at June 30, 2026. The Phase 2 melanoma expansion of NUC-7738 with pembrolizumab is ongoing, with recruitment completion and expansion data expected in 2026. The company plans to seek FDA feedback on a registration strategy and conduct a first-line Phase 1b melanoma study combining NUC-7738 with Opdualag.
2. NUC-3373 development
NuCana stopped its randomized NUC-3373 colorectal cancer trial early in 2024 after an interim analysis indicated that superior progression-free survival was unlikely. Future development may focus on combinations aligned with the drug’s mechanism, including immunomodulatory treatments.
